Diagnostic Footprint Agent

The supplied documents identify ICD-10-CM codes for Acute lymphoblastic leukemia (ALL) and remission/relapse states. The CMS ICD-10-CM release files list "C9100 — Acute lymphoblastic leukemia not having achieved remission," "C9101 — Acute lymphoblastic leukemia, in remission," and "C9102 — Acute lymphoblastic leukemia, in relapse" under "C910 — Acute lymphoblastic leukemia all." The NLM Clinical Tables additionally define ICD-10-CM code C91.01 as "Acute lymphoblastic leukemia, in remission" and ICD-10-CM code C91.02 as "Acute lymphoblastic leukemia, in relapse." The documents do not provide codes or conventions for refractory disease, secondary malignancy involvement, personal-history Z85 codes, or suspected versus confirmed diagnosis coding. The supplied documents identify ICD-9-CM acute lymphoid leukemia diagnosis codes for three disease-status categories: active disease without remission, remission, and relapse. Specifically, code 20400 is defined as "Acute lymphoid leukemia, without mention of having achieved remission," code 20401 as "Acute lymphoid leukemia, in remission," and code 20402 as "Acute lymphoid leukemia, in relapse." The documents do not provide ICD-10-CM diagnosis codes, refractory disease codes, secondary malignancy involvement codes, personal-history Z85 codes, or coding conventions for suspected versus confirmed diagnoses. The supplied documents identify ICD-9-CM leukemia codes for subacute lymphoid leukemia with distinct disease-status modifiers relevant to claims classification. Specifically, code 20420 is defined as "Subacute lymphoid leukemia, without mention of having achieved remission," code 20421 as "Subacute lymphoid leukemia, in remission," and code 20422 as "Subacute lymphoid leukemia, in relapse." The documents do not provide ICD-10-CM diagnosis codes, refractory disease codes, secondary malignancy involvement codes, personal-history Z85 codes, or coding conventions for suspected versus confirmed diagnoses. The supplied documents only identify ICD-9-CM lymphoid leukemia remission and relapse codes, not ICD-10-CM Acute Lymphoblastic Leukemia coding through 2026-09-21. The documents include code 20481 for “Other lymphoid leukemia, in remission,” code 20482 for “Other lymphoid leukemia, in relapse,” and code 20492 for “Unspecified lymphoid leukemia, in relapse.” The documents do not provide ICD-10-CM active disease codes, remission variants for ALL, refractory disease coding, secondary malignancy involvement codes, personal-history Z85 codes, or suspected-versus-confirmed diagnosis coding conventions. The supplied documents identify one ICD-10-CM code for active Acute Lymphoblastic Leukemia and one historical leukemia code from ICD-9-CM. ICD-10-CM code C91.00 is defined as "Acute lymphoblastic leukemia not having achieved remission." The documents also include ICD-9-CM code V1061, defined as "Personal history of lymphoid leukemia." The documents do not provide ICD-10-CM remission variants beyond not having achieved remission, relapse or refractory codes, secondary malignancy codes, ICD-10-CM personal-history Z85 codes, or coding conventions for suspected versus confirmed diagnoses. The supplied documents do not provide United States ICD-10-CM diagnosis codes, remission variants, relapse or refractory codes, secondary malignancy codes, personal-history Z85 codes, or suspected-versus-confirmed coding conventions for Acute Lymphoblastic Leukemia. The only coding information provided is an ICD-9-CM entry stating that code 20491 is defined as "Unspecified lymphoid leukemia, in remission." The supplied documents identify the primary ICD-10-CM Acute Lymphoblastic Leukemia (ALL) code family as C91.0 and provide specific 2026 billable diagnosis codes for active disease, remission, and relapse states: C91.00 "Acute lymphoblastic leukemia not having achieved remission," C91.01 "Acute lymphoblastic leukemia, in remission," and C91.02 "Acute lymphoblastic leukemia, in relapse." The documents also state that C91.00 is applicable to "Acute lymphoblastic leukemia with failed remission" and "Acute lymphoblastic leukemia NOS," which addresses refractory/failed-remission disease terminology within claims coding. The supplied materials do not provide specific ICD-10-CM secondary malignancy involvement codes, personal-history Z85 codes, or coding conventions distinguishing suspected versus confirmed ALL diagnoses.

The supplied documents identify one HCPCS code for a combined bone marrow aspiration and biopsy procedure, one HCPCS code for a powered bone marrow biopsy needle device, and one LOINC code for a flow cytometry study. Specifically, HCPCS code G0364 is defined as "Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service." HCPCS code C1830 is defined as "Powered bone marrow biopsy needle." The documents also include LOINC code 33719-6 for a "Flow cytometry study." The documents do not provide CPT codes, additional bone marrow biopsy or aspiration procedure codes, hematopathology service codes, or information specific to monitoring procedure use in Acute Lymphoblastic Leukemia. The supplied documents identify LOINC entries related to bone marrow biopsy, bone marrow aspiration, and flow cytometry review, but they do not provide CPT or HCPCS procedure codes. The documents include LOINC 33721-2 for a "Bone marrow Pathology biopsy report," LOINC 48807-2 for a "Bone marrow aspiration report," and LOINC 69052-9 for "Flow cytometry specialist review of results." No documents describe hematopathology CPT/HCPCS services or monitoring procedure-use coding for Acute Lymphoblastic Leukemia claims data. The supplied document does not provide CPT or HCPCS procedure codes for bone marrow biopsy, bone marrow aspiration, flow cytometry, hematopathology services, or monitoring procedures in Acute Lymphoblastic Leukemia claims data. It only identifies a LOINC entry related to bone marrow aspiration guidance: LOINC code 87008-9, defined as "Guidance for fluid aspiration of Bone marrow." The supplied document only identifies a LOINC laboratory concept related to flow cytometry and does not provide CPT or HCPCS procedure codes for bone marrow biopsy, bone marrow aspiration, hematopathology services, or monitoring procedures in Acute Lymphoblastic Leukemia. The document states that LOINC code 61126-9 is defined as "Blasts/cells in Specimen by Flow cytometry (FC)." The supplied documents do not provide CPT or HCPCS procedure codes for bone marrow biopsy, bone marrow aspiration, hematopathology services, or monitoring procedures in Acute Lymphoblastic Leukemia. The only procedure-related coding information provided is a LOINC entry for flow cytometry: LOINC code 107079-6, defined as "Blasts/Cells in Blood by Flow cytometry (FC)." It only identifies a flow cytometry-related laboratory concept: LOINC code 54226-6, defined as "Lymphoma panel - Specimen by Flow cytometry (FC)."

The supplied documents identify three LOINC laboratory codes relevant to flow cytometry testing that may be used in hematologic malignancy evaluation and monitoring. The documents provide LOINC code 61126-9 for "Blasts/cells in Specimen by Flow cytometry (FC)", LOINC code 69052-9 for "Flow cytometry specialist review of results", and LOINC code 54226-6 for "Lymphoma panel - Specimen by Flow cytometry (FC)". The documents do not provide CPT codes, cytogenetic testing codes, FISH assay codes, molecular pathology codes, genomic biomarker tests, or ALL-specific monitoring assay coding beyond these LOINC entries. The supplied documents identify several LOINC laboratory mappings relevant to hematologic evaluation and monitoring. LOINC code 61123-6 is defined as "Lymphocytes/Leukocytes in Specimen by Flow cytometry (FC)." Additional LOINC mappings include 33721-2 for a "Bone marrow Pathology biopsy report" and 48807-2 for a "Bone marrow aspiration report." The documents do not provide CPT codes, FISH assay codes, molecular pathology codes, genomic biomarker tests, or specific monitoring assay CPT mappings for Acute Lymphoblastic Leukemia classification or risk stratification. The supplied documents identify three LOINC laboratory codes relevant to flow cytometry and leukemia-related laboratory assessment. LOINC 30912-0 is defined as "DNA index in Specimen by Flow cytometry (FC)." LOINC 33719-6 is defined as "Flow cytometry study," and LOINC 107079-6 is defined as "Blasts/Cells in Blood by Flow cytometry (FC)." The documents do not provide CPT codes, cytogenetic testing codes, FISH assay codes, molecular pathology codes, genomic biomarker tests, or monitoring assay CPT mappings for Acute Lymphoblastic Leukemia. The supplied documents identify two LOINC laboratory codes potentially relevant to Acute Lymphoblastic Leukemia evaluation and monitoring. LOINC 66119-9 is defined as "Bone marrow Pathology biopsy report Narrative," and LOINC 30364-4 is defined as "Lymphocytes [#/volume] in Blood by Flow cytometry (FC)." The documents do not provide CPT codes, cytogenetic testing codes, FISH assay codes, molecular pathology codes, genomic biomarker tests, or specific monitoring assay code sets for ALL classification or risk stratification. The supplied documents only identify one LOINC laboratory mapping relevant to flow cytometry testing. LOINC code 101147-7 is defined as "Monocytes/Leukocytes in Blood by Flow cytometry (FC)." No CPT codes, cytogenetic testing codes, FISH assay codes, molecular pathology codes, genomic biomarker tests, or monitoring assay codes specific to Acute Lymphoblastic Leukemia classification, risk stratification, or monitoring are provided in the documents. The supplied documents only identify one LOINC laboratory code related to flow cytometry and do not provide CPT codes, cytogenetic testing codes, FISH assay codes, molecular pathology codes, genomic biomarker tests, or monitoring assay mappings for Acute Lymphoblastic Leukemia. The available document states that LOINC code 104548-3 corresponds to "Monocytes [#/volume] in Blood by Flow cytometry (FC)." The supplied documents do not provide CPT codes, cytogenetic testing codes, FISH assay codes, molecular pathology codes, genomic biomarker tests, or monitoring assay codes relevant to Acute Lymphoblastic Leukemia. The only laboratory mapping identified is the LOINC code 26028-1, defined as "HLA-B27 presence by Flow cytometry (FC)." The documents identify several CPT codes for fluorescence in situ hybridization (FISH) testing relevant to Acute Lymphoblastic Leukemia (ALL): "CPT Code(s): 88237, 88275 (x per analyses), 88271 (x per probe)." The FISH panels include genomic targets used for ALL classification, prognostic assessment, and monitoring, including "t(9;22) (BCR/ABL1), 11q23.3 (KMT2A, formerly MLL), t(12;21) (ETV6/RUNX1)," as well as CRLF2, ABL1, ABL2, PDGFRB, PBX1;TCF3, and CDKN2A. The documents also state that "FISH is useful to identify chromosome abnormalities in patients with pediatric or adult acute lymphoblastic leukemia (ALL) for diagnostic and prognostic purposes as well as for follow-up to evaluate patient response to therapy" and that "Companion testing with chromosome analysis is recommended." No LOINC codes, specific cytogenetic chromosome analysis CPT codes beyond the listed FISH-related CPTs, or broader molecular pathology/genomic laboratory billing codes are provided in the supplied documents.

The supplied documents identify ICD-9-CM legacy Acute Lymphoid Leukemia diagnosis codes and one ICD-10-CM Acute Lymphoblastic Leukemia concept. ICD-9-CM code 20401 is defined as "Acute lymphoid leukemia, in remission," and ICD-9-CM code 20402 is defined as "Acute lymphoid leukemia, in relapse." The CMS ICD-10-CM release file excerpt lists ICD-10-CM concept C910 "Acute lymphoblastic leukemia all" with subcode C9100 "Acute lymphoblastic leukemia not having achieved remission." The documents do not provide ICD-9-CM to ICD-10-CM crosswalk mappings, ICD-11 stem or extension codes, linkage rules, or effective, revision, and retirement dates across annual coding updates. The supplied documents identify two ICD-10-CM concepts for Acute Lymphoblastic Leukemia. ICD-10-CM code C91.01 is defined as "Acute lymphoblastic leukemia, in remission," and ICD-10-CM code C91.02 is defined as "Acute lymphoblastic leukemia, in relapse." The documents do not provide ICD-9-CM legacy leukemia mappings, ICD-11 stem or extension code mappings, linkage information, or any effective, revision, or retirement dates across annual coding updates. The supplied documents identify ICD-10-CM concepts for Acute Lymphoblastic Leukemia (ALL) and provide some annual update and effective-date information, but they do not provide ICD-9-CM legacy leukemia code mappings, ICD-11 stem-code mappings, ICD-11 extension-code linkage, or retirement-date histories. The documents state that “The ICD-10 code for acute lymphoblastic leukemia is C91.0, with specific codes for remission status,” and list the ICD-10-CM remission-status concepts “C91.00,” “C91.01,” and “C91.02.” The 2026 ICD-10-CM update documentation states that “The 2026 edition of ICD-10-CM C91.00 became effective on October 1, 2025,” and displays annual code-set continuity for “20162017201820192020202120222023202420252026.” No supplied document contains ICD-9-CM to ICD-10-CM crosswalks, ICD-11 mappings, revision histories beyond the cited annual editions, or retirement dates.

The supplied documents identify Acute Lymphoblastic Leukemia diagnosis coding, including ICD-10-CM code C91.0 and related remission-status codes C91.00, C91.01, and C91.02. The documents also mention that ALL treatment can include “radiation therapy” and “stem cell transplant,” but they do not provide CPT, HCPCS, ICD-10-PCS, leukapheresis, cellular collection, conditioning regimen, CAR-T administration, or specific procedure codes requested in the question.

The supplied documents identify ICD-10-CM diagnosis codes for Acute Lymphoblastic Leukemia (ALL), including remission and relapse status codes. However, the documents do not provide any information on clinical trial diagnosis codes, HCPCS modifiers such as Q0 or Q1, investigational service indicators, routine clinical trial care billing indicators, or revenue code markers for claims-based line-of-therapy analyses. The supplied documents only identify one Acute Lymphoblastic Leukemia diagnosis code: ICD-10-CM code C91.02, defined as “Acute lymphoblastic leukemia, in relapse.” The documents do not provide any information on clinical trial diagnosis codes, HCPCS modifiers Q0 or Q1, investigational service indicators, routine trial care billing markers, or revenue code indicators for claims-based line-of-therapy analyses. The supplied documents identify one Acute Lymphoblastic Leukemia diagnosis code relevant to claims-based analyses: ICD-10-CM code C91.00, defined as “Acute lymphoblastic leukemia not having achieved remission.” The documents do not provide information on clinical trial diagnosis codes, HCPCS modifiers Q0 or Q1, investigational service indicators, routine trial care billing, or revenue code markers. The supplied documents do not provide the requested diagnosis codes, HCPCS modifiers such as Q0 and Q1, revenue codes, investigational service indicators, or routine clinical trial billing markers specific to claims-based line-of-therapy analyses in Acute Lymphoblastic Leukemia patients. The documents only establish that HCPCS includes categories related to “Administrative, Miscellaneous and Investigational” services and that CMS maintains annually updated CPT/HCPCS code lists through 2026. No document in the set identifies specific clinical trial participation diagnosis codes, Q0/Q1 modifier definitions, or revenue code indicators for investigational or routine trial-related care.